Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

BACKGROUND: Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combination cediranib/olaparib improved progression-free survival (PFS) compared with olaparib alone in relapsed platinum-sensitive ovarian cancer...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Liu, J F, Barry, W T, Birrer, M, Lee, J -M, Buckanovich, R J, Fleming, G F, Rimel, B J, Buss, M K, Nattam, S R, Hurteau, J, Luo, W, Curtis, J, Whalen, C, Kohn, E C, Ivy, S P, Matulonis, U A
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6503628/
https://ncbi.nlm.nih.gov/pubmed/30753272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz018
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares